Instrument Inactif

Gouvernance Sarepta Therapeutics Inc Nasdaq

US0023461041

Produits pharmaceutiques

Cours en clôture Nasdaq
- ^USD	-

14/09	Transcript : Sarepta Therapeutics, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-14-2026 08:30 AM
08/09	Dyne et Sarepta chutent : le revers de Novartis pèse sur les développeurs de traitements contre les maladies musculaires	RE

Comité Exécutif: Sarepta Therapeutics Inc

Dirigeant

Fonctions occupéesDepuis

Michael Severino

60 ans

Chief Executive Officer

28/07/2026

Tam Thornton

Investor Relations Contact

01/02/2023

James Richardson

Chief Tech/Sci/R&D Officer

01/02/2025

Rachael Potter

Chief Tech/Sci/R&D Officer

Ryan Wong

47 ans

Director of Finance/CFO

16/07/2025

Cristin Rothfuss

58 ans

General Counsel

01/02/2021

Alison Nasisi

Human Resources Officer

01/10/2021

Louise Rodino-Klapac

48 ans

Chief Tech/Sci/R&D Officer

14/12/2020

Ian Estepan

50 ans

Chief Operating Officer	16/07/2025
President	16/07/2025

Composition du Conseil d'Administration: Sarepta Therapeutics Inc

Administrateur

ComitésDepuis

M. Wilsey

73 ans

Audit Committee Chair
Audit Committee	19/06/2019
Governance Committee	19/06/2019
Nominating Committee	19/06/2019

Deirdre Connelly

65 ans

Compensation Committee	26/03/2020
Governance Committee Chair
Nominating Committee Chair
Audit Committee	26/03/2020
Executive Committee
Governance Committee	12/09/2024
Compensation Committee Chair	12/09/2024
Finance Committee	26/03/2020
Nominating Committee	12/09/2024

Claude Nicaise

74 ans

Compensation Committee	01/02/2021
Governance Committee	09/09/2024
Nominating Committee	09/09/2024
Audit Committee Chair
Compensation Committee Chair	09/09/2024

Kathryn Boor

67 ans

Compensation Committee	02/06/2022
Governance Committee Chair	01/01/2019
Nominating Committee Chair	01/01/2019
Governance Committee	02/06/2022
Nominating Committee	02/06/2022

Richard Barry

67 ans

Audit Committee	02/06/2015
Compensation Committee	02/06/2015
Governance Committee Chair	02/06/2015
Nominating Committee Chair	02/06/2015

Michael Severino

60 ans

Compensation Committee Chair
HR Committee Chair
Audit Committee	05/05/2025

Hans Lennart Rudolf Wigzell

87 ans

Governance Committee	05/05/2015
Nominating Committee	05/05/2015

Stephen Mayo

64 ans

Audit Committee

12/07/2022

Michael Chambers

51 ans

Director/Board Member	02/06/2022
Independent Dir/Board Member	02/06/2022

Anciens Dirigeants et Administrateurs: Sarepta Therapeutics Inc

Insider

Fonctions occupées

DepuisJusqu'au

Douglas Ingram

Director/Board Member	04/06/2026	28/07/2026
Chief Executive Officer	26/06/2017	28/07/2026
President	26/06/2017	16/07/2025

Jayant Aphale

Corporate Officer/Principal

14/12/2011

01/01/2024

Mary Gray

Director/Board Member	11/12/2018	02/06/2022
Independent Dir/Board Member	11/12/2018	02/06/2022

Gilmore O’Neill

Chief Tech/Sci/R&D Officer

07/06/2018

17/11/2021

Joan Nickerson

Human Resources Officer

01/10/2016

01/04/2021

TY Howton

General Counsel	05/11/2012	-
Corporate Secretary	05/11/2012	14/12/2020

Alexander Cumbo

Corporate Officer/Principal

01/01/2013

01/10/2020

Sandy Mahatme

Director of Finance/CFO

05/11/2012

10/07/2020

Michael Bonney

Director/Board Member	05/12/2017	18/03/2020
Independent Dir/Board Member	05/12/2017	18/03/2020

Guriqbal S. Basi

Chief Tech/Sci/R&D Officer

25/09/2017

01/09/2018

Gary Charbonneau

General Counsel

01/05/2018

Shamim Ruff

General Counsel

01/01/2013

01/05/2018

Catherine Stehman-Breen

Chief Tech/Sci/R&D Officer

01/03/2017

01/12/2017

Edward Kaye

Director/Board Member	20/09/2016	01/08/2017
Chief Executive Officer	01/04/2015	01/07/2017
Chief Tech/Sci/R&D Officer	01/06/2011	01/03/2017
President	20/09/2016	01/07/2017

Jean-Paul Kress

Director/Board Member	30/09/2015	06/06/2017
Independent Dir/Board Member	30/09/2015	06/06/2017

Joan Wood

Human Resources Officer

01/04/2015

01/03/2017

William Goolsbee

Director/Board Member	30/07/2014	01/01/2016
Chairman	30/10/2007	30/07/2014
Independent Dir/Board Member	30/10/2007	01/01/2016

Gavin Malenfant

Chief Operating Officer

01/05/2015

01/01/2016

Ben Price

Director/Board Member	30/10/2007	01/01/2016
Independent Dir/Board Member	30/10/2007	01/01/2016

John C. Hodgman

Director/Board Member	01/03/2004	01/06/2015
Chairman	30/07/2014	16/04/2015
Independent Dir/Board Member	01/03/2004	01/06/2015

Christopher Garabedian

Director/Board Member	11/06/2010	01/04/2015
Chief Executive Officer	11/01/2011	01/04/2015
Director of Finance/CFO	29/07/2011	05/11/2012
President	11/01/2011	01/04/2015

Stephan Toutain

Corporate Officer/Principal

01/01/2014

01/01/2015

Arthur M. Krieg

Chief Tech/Sci/R&D Officer

09/01/2014

22/07/2014

Erin S. Cox

Investor Relations Contact

01/08/2011

01/05/2014

Kathryn Haviland

Corporate Officer/Principal

01/06/2012

01/04/2014

Marco A. Passini

Corporate Officer/Principal

01/01/2017

Anthony Martgnetti

Comptroller/Controller/Auditor

01/10/2013

04/10/2013

Michael Jacobsen

Comptroller/Controller/Auditor	08/09/2011	-
Director of Finance/CFO	09/09/2011	15/11/2011
Corporate Officer/Principal	08/09/2011	08/09/2011
Corporate Secretary	07/09/2011	22/04/2013

Peter S. Linsley

Chief Tech/Sci/R&D Officer

01/05/2011

01/06/2012

Effie Toshav

General Counsel	10/01/2011	24/02/2012
Corporate Secretary	10/01/2011	24/02/2012

Patrick L. Iversen

Chief Tech/Sci/R&D Officer	18/02/2011	01/01/2012
Corporate Officer/Principal	01/01/1997	18/02/2011

Melinda Miles

Comptroller/Controller/Auditor

29/07/2011

06/09/2011

J. Boyle

Comptroller/Controller/Auditor	07/07/2010	24/07/2011
Director of Finance/CFO	18/08/2008	24/07/2011
President	22/04/2010	11/01/2011
Corporate Secretary	22/04/2010	24/07/2011

Stephen Shrewsbury

Chief Tech/Sci/R&D Officer	01/02/2009	20/06/2011
General Counsel	01/02/2009	20/06/2011

Paul Medeiros

Corporate Officer/Principal

19/05/2009

01/06/2011

Graham Johnson

Chief Tech/Sci/R&D Officer

06/09/2010

13/05/2011

Michael D. Casey

Chairman

01/05/2006

07/06/2010

Christopher Henney

Director/Board Member

01/04/2009

01/06/2010

K. Michael Forrest

Director/Board Member	01/03/2005	21/04/2010
Chief Executive Officer	28/03/2007	21/04/2010

Anthony Chase

Director/Board Member	22/04/2010	-
Independent Dir/Board Member	21/04/2010	-

Leslie Hudson

Chief Executive Officer	08/02/2008	20/04/2010
Chief Operating Officer	11/02/2008	20/04/2010
President	11/02/2008	20/04/2010

Jacqueline A. Dombroski

General Counsel

16/02/2010

John Fara

Director/Board Member

01/05/2000

31/03/2009

Peter D. O'Hanley

Chief Tech/Sci/R&D Officer	01/03/2004	09/01/2009
General Counsel	01/03/2004	09/01/2009

Gunnar J. Hanson

Corporate Officer/Principal

01/01/2009

Alan P. Timmins

Chief Operating Officer	01/01/1992	18/09/2008
President	01/01/1992	18/09/2008

Shirley J. Leow

Chief Tech/Sci/R&D Officer	01/08/2008	15/11/2011
Corporate Officer/Principal	15/11/2011	-

Ryszard Kole

Corporate Officer/Principal

10/04/2008

Jack L. Bowman

Chairman

01/03/2004

10/03/2008

James Hicks

Director/Board Member

01/01/1997

29/10/2007

Denis Burger

Chief Executive Officer	01/01/1996	27/03/2007
Chairman	01/01/1996	27/03/2007

Joseph B. Horn

Corporate Officer/Principal

01/01/2005

R. Ray Cummings

Corporate Officer/Principal

01/04/2004

Janet Rose Christensen

General Counsel

01/01/2003

Mark M. Webber

Chief Administrative Officer

01/10/1997

Dwight D. Weller

Corporate Officer/Principal

01/01/1991

Kara Boniface

Corporate Officer/Principal

Sarah J. Bard

Corporate Officer/Principal

Jim Baker

Public Communications Contact

David Walsey

Public Communications Contact

Michael W. Dochterman

Director/Board Member	-	19/05/2009
Chairman	19/05/2009	-

Julie Rathbun

Public Communications Contact

Michael Hubbard

Public Communications Contact

Raymond W. Ruddon

Director/Board Member

Joseph Rubinfeld

Director/Board Member

Distribution de l'Âge des Dirigeants

Parité Homme Femme

Homme	16
Femme	4

Dont comité exécutif

Homme	6
Femme	3

Dont Administrateurs

Homme	8
Femme	1

Sarepta Therapeutics, Inc. est une société biopharmaceutique ayant atteint le stade commercial. La société s'attache à venir en aide aux patients par la découverte et le développement de traitements ciblant l'acide ribonucléique (ARN), de thérapies par inhibition de l'ARNsi, de thérapies géniques et d'autres modalités thérapeutiques génétiques destinées au traitement des maladies rares. Elle a développé plusieurs produits approuvés pour le traitement de la dystrophie musculaire de Duchenne (Duchenne) et développe actuellement des candidats thérapeutiques potentiels pour toute une série de maladies et de troubles, notamment la dystrophie de Duchenne, les dystrophies musculaires des ceintures (LGMD) et d’autres troubles liés au système neuromusculaire et au système nerveux central (SNC). La société a développé et commercialisé quatre produits approuvés pour le traitement de la dystrophie de Duchenne : EXONDYS 51 (eteplirsen), solution injectable (EXONDYS 51), VYONDYS 53 (golodirsen), solution injectable (VYONDYS 53), AMONDYS 45 (casimersen), solution injectable (AMONDYS 45), et ELEVIDYS.

Employés

Secteur

Produits pharmaceutiques

Plus d'informations sur la société